Calcimedica, INC Form 4 insider transactions

Director Robert N. Wilson of CalciMedica, Inc. purchased 51,278 shares of common stock at an average price of $3.52 on June 28, 2024.

Director Robert N. Wilson of CalciMedica, Inc. reports purchasing 8,443 shares of common stock at an average price of $3.234.

Eric W. Roberts, Chief Business Officer of CalciMedica, recently acquired 5,000 shares of common stock at $3.22 per share, increasing his total holdings.

Daniel E. Geffken, Interim CFO of CalciMedica, Inc., reports the acquisition of warrants exercisable for 10,000 shares of common stock.

Director Frederic Guerard received stock options for 10,000 shares of CalciMedica, Inc. at an exercise price of $4.16, vesting monthly over one year.

Director Eric Bjerkhult received stock options for 10,000 shares of CalciMedica, Inc. at an exercise price of $4.16 on March 28, 2024.

Director Allan Shaw acquired stock options for 10,000 shares of CalciMedica, Inc. at an exercise price of $4.16 on March 28, 2024.

Director Fred A. Middleton receives stock options for 10,000 shares in CalciMedica, Inc.

Director Robert N. Wilson of CalciMedica, Inc. reports acquisition of stock options.

Michael J. Dunn, President and COO of CalciMedica, reports the acquisition of employee stock options.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., acquired employee stock options on March 28, 2024.

Eric W. Roberts, Chief Business Officer of CalciMedica, reports the acquisition of stock options.

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, reports the acquisition of stock options.

Rachel Leheny, CEO of CalciMedica, Inc., was granted employee stock options on March 28, 2024.

Eric W. Roberts, Chief Business Officer of CalciMedica, Inc., reports purchases of common stock through a Roth IRA.